Skip to main content
Erschienen in: Inflammation 3/2015

01.06.2015

In Vitro Oxidation of Fibrinogen Promotes Functional Alterations and Formation of Advanced Oxidation Protein Products, an Inflammation Mediator

verfasst von: Vanessa Dorneles Torbitz, Guilherme Vargas Bochi, José Antônio Mainardi de Carvalho, Rodrigo de Almeida Vaucher, José Edson Paz da Silva, Rafael Noal Moresco

Erschienen in: Inflammation | Ausgabe 3/2015

Einloggen, um Zugang zu erhalten

Abstract

Fibrinogen (FB) is a soluble blood plasma protein and is a key molecule involved in coagulation. Oxidative modification of proteins, such as the formation of advanced oxidation protein products (AOPP), a heterogeneous family of protein compounds structurally modified and derived from oxidative stress, may be associated with the pathophysiology of a number of chronic inflammatory diseases. Therefore, the aim of this study was to determine whether the formation of this mediator of inflammation occurs from FB and whether its generation is associated with structural changes. Results of the present study suggest that the oxidation of FB may provoke the formation of AOPP, which in turn, may promote functional alterations in FB, thus causing changes in its structural domains and increasing its procoagulant activity.
Literatur
1.
Zurück zum Zitat Liu, C.Y., H.L. Nossel, and K.L. Kaplan. 1979. The binding of thrombin by fibrin. The Journal of Biological Chemistry 254: 10421–10425.PubMed Liu, C.Y., H.L. Nossel, and K.L. Kaplan. 1979. The binding of thrombin by fibrin. The Journal of Biological Chemistry 254: 10421–10425.PubMed
2.
Zurück zum Zitat Collen, D., G. Tygat, H. Claeys, and R. Piessens. 1972. Metabolism and distribution of fibrinogen. I. Fibrinogen turnover in physiological conditions in humans. British Journal of Haematology 22: 681–700.CrossRefPubMed Collen, D., G. Tygat, H. Claeys, and R. Piessens. 1972. Metabolism and distribution of fibrinogen. I. Fibrinogen turnover in physiological conditions in humans. British Journal of Haematology 22: 681–700.CrossRefPubMed
3.
Zurück zum Zitat Brow, J.H., N. Volkmann, G. Jun, A.H. Henschen-Edman, and C. Cohen. 2000. The crystal structure of modified bovine fibrinogen. Proceedings of National Academy of Sciences of the United States of America 97: 85–90.CrossRef Brow, J.H., N. Volkmann, G. Jun, A.H. Henschen-Edman, and C. Cohen. 2000. The crystal structure of modified bovine fibrinogen. Proceedings of National Academy of Sciences of the United States of America 97: 85–90.CrossRef
4.
Zurück zum Zitat Hall, C.E., and H.S. Slayter. 1959. The fibrinogen molecule: its size, shape, and mode of polymerization. The Journal of the Biophysical and Biochemical Cytology 5: 11–16.CrossRef Hall, C.E., and H.S. Slayter. 1959. The fibrinogen molecule: its size, shape, and mode of polymerization. The Journal of the Biophysical and Biochemical Cytology 5: 11–16.CrossRef
5.
Zurück zum Zitat Kollman, J.M., L. Pandi, M.R. Sawaya, M. Riley, and R.F. Doolittle. 2009. Crystal structure of human fibrinogen. Biochemistry 48: 3877–3886.CrossRefPubMed Kollman, J.M., L. Pandi, M.R. Sawaya, M. Riley, and R.F. Doolittle. 2009. Crystal structure of human fibrinogen. Biochemistry 48: 3877–3886.CrossRefPubMed
6.
Zurück zum Zitat Budzynski, A.Z., S.A. Olexa, and B.V. Pandya. 1983. Fibrin polymerization sites in fibrinogen and fibrin fragments. Annals of the New York Academy of Sciences 408: 301–314.CrossRefPubMed Budzynski, A.Z., S.A. Olexa, and B.V. Pandya. 1983. Fibrin polymerization sites in fibrinogen and fibrin fragments. Annals of the New York Academy of Sciences 408: 301–314.CrossRefPubMed
7.
Zurück zum Zitat Martinez, M., J.W. Weisel, and H. Ischiropoulos. Functional impact of oxidative posttranslational modifications on fibrinogen and fibrin clots. 2013. Free Radical Biology and Medicine 65: 411-418. Martinez, M., J.W. Weisel, and H. Ischiropoulos. Functional impact of oxidative posttranslational modifications on fibrinogen and fibrin clots. 2013. Free Radical Biology and Medicine 65: 411-418.
8.
Zurück zum Zitat Dalle-Donne, I., R. Rossi, D. Giustarini, A. Milzani, and R. Colombo. 2003. Protein carbonyl groups as biomarkers of oxidative stress. Clinica Chimica Acta 329: 23–38.CrossRef Dalle-Donne, I., R. Rossi, D. Giustarini, A. Milzani, and R. Colombo. 2003. Protein carbonyl groups as biomarkers of oxidative stress. Clinica Chimica Acta 329: 23–38.CrossRef
9.
Zurück zum Zitat Witko-Sarsat, V., M. Friedlander, C. Capeillère-Blandin, A.T. Nguyen-Khoa, A.T. Nguyen, J. Zingraff, P. Jungers, et al. 1996. Advanced oxidation protein products as a novel marker of oxidative stress in uremia. Kidney International 49: 1304–1313.CrossRefPubMed Witko-Sarsat, V., M. Friedlander, C. Capeillère-Blandin, A.T. Nguyen-Khoa, A.T. Nguyen, J. Zingraff, P. Jungers, et al. 1996. Advanced oxidation protein products as a novel marker of oxidative stress in uremia. Kidney International 49: 1304–1313.CrossRefPubMed
10.
Zurück zum Zitat Capeillere-Blandin, C., V. Gausson, B. Descamps-Latscha, and V. Witko-Sarsat. 2004. Biochemical and spectrophotometric significance of advanced oxidized protein products. Biochimica et Biophysica Acta 1689: 91–102.CrossRefPubMed Capeillere-Blandin, C., V. Gausson, B. Descamps-Latscha, and V. Witko-Sarsat. 2004. Biochemical and spectrophotometric significance of advanced oxidized protein products. Biochimica et Biophysica Acta 1689: 91–102.CrossRefPubMed
11.
Zurück zum Zitat Selmeci, L., M. Székely, P. Soós, L. Seres, N. Klinga, and A. Geiger. 2006. Human blood plasma advanced oxidation protein products (AOPP) correlates with fibrinogen levels. Free Radical Research 40: 952–958.CrossRefPubMed Selmeci, L., M. Székely, P. Soós, L. Seres, N. Klinga, and A. Geiger. 2006. Human blood plasma advanced oxidation protein products (AOPP) correlates with fibrinogen levels. Free Radical Research 40: 952–958.CrossRefPubMed
12.
Zurück zum Zitat Bochi, G.V., V.D. Torbitz, L.P. Cargnin, M.B. Sangoi, R.C. Santos, P. Gomes, et al. 2012. Fructose-1,6-bisphosphate and N-acetylcysteine attenuate the formation of advanced oxidation protein products, a new class of inflammatory mediators, in vitro. Inflammation 35: 1786–1792.CrossRefPubMed Bochi, G.V., V.D. Torbitz, L.P. Cargnin, M.B. Sangoi, R.C. Santos, P. Gomes, et al. 2012. Fructose-1,6-bisphosphate and N-acetylcysteine attenuate the formation of advanced oxidation protein products, a new class of inflammatory mediators, in vitro. Inflammation 35: 1786–1792.CrossRefPubMed
13.
Zurück zum Zitat Hanasand, M., R. Omdal, K.B. Norheim, L.G. Gøransson, C. Brede, and G. Jonsson. 2013. Improved detection of advanced oxidation protein products in plasma. Clinica Chimica Acta 413: 901–906.CrossRef Hanasand, M., R. Omdal, K.B. Norheim, L.G. Gøransson, C. Brede, and G. Jonsson. 2013. Improved detection of advanced oxidation protein products in plasma. Clinica Chimica Acta 413: 901–906.CrossRef
14.
Zurück zum Zitat Carr, Jr., and J. Hermans. 1978. Size and density of fibrin fibers from turbidity. Macromolecules 11: 46–50.CrossRefPubMed Carr, Jr., and J. Hermans. 1978. Size and density of fibrin fibers from turbidity. Macromolecules 11: 46–50.CrossRefPubMed
15.
Zurück zum Zitat Laemmli, U.K. 1970. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227: 680–685.CrossRefPubMed Laemmli, U.K. 1970. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227: 680–685.CrossRefPubMed
16.
Zurück zum Zitat Witko-Sarsat, V., V. Gausson, A.T. Nguyen, M. Touam, T. Drüeke, F. Santangelo, et al. 2003. AOPP-induced activation of human neutrophil and monocyte oxidative metabolism: a potential target for N-acetylcysteine treatment in dialysis patients. Kidney International 64: 82–91.CrossRefPubMed Witko-Sarsat, V., V. Gausson, A.T. Nguyen, M. Touam, T. Drüeke, F. Santangelo, et al. 2003. AOPP-induced activation of human neutrophil and monocyte oxidative metabolism: a potential target for N-acetylcysteine treatment in dialysis patients. Kidney International 64: 82–91.CrossRefPubMed
17.
Zurück zum Zitat Margret, C.M., and C.C. Winterbourn. 1991. Oxidative damage to fibrinonectin I. Effects of the Neutrophil myeloperoxidase system and HOCl. The Archieves of Biochemistry and Biophysics 15: 53–59. Margret, C.M., and C.C. Winterbourn. 1991. Oxidative damage to fibrinonectin I. Effects of the Neutrophil myeloperoxidase system and HOCl. The Archieves of Biochemistry and Biophysics 15: 53–59.
18.
Zurück zum Zitat Weigandt, K.M., N. White, D. Chung, E. Ellingson, Y. Wang, and X. Fu. 2012. Fibrin clot structure and mechanics associated with specific oxidation of methionine residues in fibrinogen. Biophysical Journal 103: 2399–2407.CrossRefPubMedCentralPubMed Weigandt, K.M., N. White, D. Chung, E. Ellingson, Y. Wang, and X. Fu. 2012. Fibrin clot structure and mechanics associated with specific oxidation of methionine residues in fibrinogen. Biophysical Journal 103: 2399–2407.CrossRefPubMedCentralPubMed
19.
Zurück zum Zitat Kannel, W.B., P.A. Wolf, W.P. Castelli, and R.B. D’Agostino. 1987. Fibrinogen and risk of cardiovascular disease. The Framingham Study. JAMA 258: 1183–1186.CrossRefPubMed Kannel, W.B., P.A. Wolf, W.P. Castelli, and R.B. D’Agostino. 1987. Fibrinogen and risk of cardiovascular disease. The Framingham Study. JAMA 258: 1183–1186.CrossRefPubMed
20.
Zurück zum Zitat Stec, J.J., H. Silbershatz, G.H. Tofler, T.H. Matheney, P. Sutherland, I. Lipinska, et al. 2000. Association of fibrinogen with cardiovascular risk factors and cardiovascular disease in the Framingham Offspring Population. Circulation 102: 1634–1638.CrossRefPubMed Stec, J.J., H. Silbershatz, G.H. Tofler, T.H. Matheney, P. Sutherland, I. Lipinska, et al. 2000. Association of fibrinogen with cardiovascular risk factors and cardiovascular disease in the Framingham Offspring Population. Circulation 102: 1634–1638.CrossRefPubMed
21.
Zurück zum Zitat Upchurch Jr., G.R., N. Ramdev, M.T. Walsh, and J. Loscalzo. 1998. Prothrombotic consequences of the oxidation of fibrinogen and their inhibition by aspirin. Journal of Thrombosis and Thrombolysis 5: 9–14.CrossRef Upchurch Jr., G.R., N. Ramdev, M.T. Walsh, and J. Loscalzo. 1998. Prothrombotic consequences of the oxidation of fibrinogen and their inhibition by aspirin. Journal of Thrombosis and Thrombolysis 5: 9–14.CrossRef
22.
Zurück zum Zitat Belisario, M.A., C. Di Domenico, A. Pelagalli, R. Della Morte, and N. Staiano. 1997. Metal-ion catalyzed oxidation affects fibrinogen activity on platelet aggregation and adhesion. Biochimie 79: 449–455.CrossRefPubMed Belisario, M.A., C. Di Domenico, A. Pelagalli, R. Della Morte, and N. Staiano. 1997. Metal-ion catalyzed oxidation affects fibrinogen activity on platelet aggregation and adhesion. Biochimie 79: 449–455.CrossRefPubMed
Metadaten
Titel
In Vitro Oxidation of Fibrinogen Promotes Functional Alterations and Formation of Advanced Oxidation Protein Products, an Inflammation Mediator
verfasst von
Vanessa Dorneles Torbitz
Guilherme Vargas Bochi
José Antônio Mainardi de Carvalho
Rodrigo de Almeida Vaucher
José Edson Paz da Silva
Rafael Noal Moresco
Publikationsdatum
01.06.2015
Verlag
Springer US
Erschienen in
Inflammation / Ausgabe 3/2015
Print ISSN: 0360-3997
Elektronische ISSN: 1573-2576
DOI
https://doi.org/10.1007/s10753-014-0085-x

Weitere Artikel der Ausgabe 3/2015

Inflammation 3/2015 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.